En undersøgelse af lægemidlet Selinexor med strålebehandling hos patienter med nyligt diagnosticeret diffust intrinsisk pontin (DIPG) gliom og højgradigt gliom (HGG)
Et fase 1/2-forsøg med Selinexor (KPT-330) og strålebehandling i nyligt diagnosticeret pædiatrisk diffust intrinsisk pontinsk gliom (DIPG) og højgradigt gliom (HGG)
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). This trial has two parts. The only difference in treatment between the two parts is that some subjects treated in Part 1 may receive a different dose of selinexor than the subjects treated in Part 2. In Part 1 (also called the Dose-Finding Phase), investigators want to determine the dose of selinexor that can be given without causing side effects that are too severe. This dose is called the maximum tolerated dose (MTD). In Part 2 (also called the Efficacy Phase), investigators want to find out how effective the MTD of selinexor is against HGG or DIPG. Selinexor blocks a protein called CRM1, which may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor called selective inhibitors of nuclear export (SINE). Radiation therapy uses high energy to kill tumor cells and shrink tumors. The combination of selinexor and radiation therapy may be effective in treating patients with newly-diagnosed DIPG and H3 K27M-Mutant HGG.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To define toxicities and estimate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of selinexor administered as an oral formulation in combination with standard of care radiation therapy (RT), to pediatric patients with newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). (Dose-finding phase/phase I) II. To estimate the event-free survival (EFS) distribution for diffuse midline glioma (DMG)/HGG patients and overall survival (OS) distribution for DIPG patients associated with selinexor plus RT, followed by selinexor in patients with newly diagnosed HGG (H3 K27M mutant DMG or H3 K27-wild type HGG) or DIPG, and to compare those outcomes to historical controls. (Efficacy phase/phase II)
EXPLORATORY OBJECTIVE:
I. To bank tumor specimens and body fluids (blood and cerebrospinal fluid) for future studies.
OUTLINE: This is a phase I dose-escalation study of selinexor followed by a phase II study. (STRATUM DIPG AND STRATUM DMG CLOSED TO ACCRUAL 02/14/2025)
CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor orally (PO) on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a magnetic resonance imaging (MRI) and may undergo a biopsy during screening.
MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up.
After completion of study treatment, patients are followed every 3 months for year 1 (i.e., 3, 6, 9, 12 months), then every 6 months for years 2-3 (i.e., 18, 24, 30, 36 months), and finally once yearly for years 4-5 of this study.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Sydney Children's Hospital
-
Westmead, New South Wales, Australien, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Queensland Children's Hospital
-
-
Victoria
-
Parkville, Victoria, Australien, 3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australien, 6009
- Perth Children's Hospital
-
-
-
-
-
Québec, Canada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Canada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- Jim Pattison Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- Children's Hospital of Alabama
-
-
Arizona
-
Mesa, Arizona, Forenede Stater, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Forenede Stater, 85016
- Phoenix Childrens Hospital
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Loma Linda, California, Forenede Stater, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Forenede Stater, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Forenede Stater, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forenede Stater, 90027
- Children's Hospital Los Angeles
-
Madera, California, Forenede Stater, 93636
- Valley Children's Hospital
-
Oakland, California, Forenede Stater, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Forenede Stater, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Forenede Stater, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Forenede Stater, 94304
- Lucile Packard Children's Hospital Stanford University
-
San Diego, California, Forenede Stater, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Forenede Stater, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Children's Hospital Colorado
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Forenede Stater, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Forenede Stater, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Children's National Medical Center
-
-
Florida
-
Fort Myers, Florida, Forenede Stater, 33908
- Golisano Children's Hospital of Southwest Florida
-
Jacksonville, Florida, Forenede Stater, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Forenede Stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Forenede Stater, 33176
- Miami Cancer Institute
-
Orlando, Florida, Forenede Stater, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Forenede Stater, 32806
- Arnold Palmer Hospital for Children
-
St. Petersburg, Florida, Forenede Stater, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Forenede Stater, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Peoria, Illinois, Forenede Stater, 61637
- OSF Children's Hospital of Illinois
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Riley Hospital for Children
-
-
Iowa
-
Des Moines, Iowa, Forenede Stater, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Forenede Stater, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Forenede Stater, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Forenede Stater, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Forenede Stater, 48201
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Forenede Stater, 55455
- University of Minnesota/Masonic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forenede Stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forenede Stater, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Forenede Stater, 68114
- Children's Hospital and Medical Center of Omaha
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Forenede Stater, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Forenede Stater, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Forenede Stater, 07503
- Saint Joseph's Regional Medical Center
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Albany Medical Center
-
Buffalo, New York, Forenede Stater, 14263
- Roswell Park Cancer Institute
-
New Hyde Park, New York, Forenede Stater, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forenede Stater, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Forenede Stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Syracuse, New York, Forenede Stater, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Forenede Stater, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Forenede Stater, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Forenede Stater, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Forenede Stater, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Forenede Stater, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Forenede Stater, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Oregon Health and Science University
-
Portland, Oregon, Forenede Stater, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Danville, Pennsylvania, Forenede Stater, 17822
- Geisinger Medical Center
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Forenede Stater, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Forenede Stater, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Forenede Stater, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Forenede Stater, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, Forenede Stater, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Forenede Stater, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Forenede Stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Forenede Stater, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Forenede Stater, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Forenede Stater, 76104
- Cook Children's Medical Center
-
Houston, Texas, Forenede Stater, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Forenede Stater, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
San Antonio, Texas, Forenede Stater, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Forenede Stater, 78207
- Children's Hospital of San Antonio
-
Temple, Texas, Forenede Stater, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84113
- Primary Children's Hospital
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- University of Virginia Cancer Center
-
Norfolk, Virginia, Forenede Stater, 23507
- Children's Hospital of The King's Daughters
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Forenede Stater, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Forenede Stater, 98405
- Mary Bridge Children's Hospital and Health Center
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Children's Hospital of Wisconsin
-
-
-
-
-
Christchurch, New Zealand, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, New Zealand, 1145
- Starship Children's Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
PRE ENROLLMENT: Patients must be =< 25 years of age at the time of enrollment on APEC14B1 part A central nervous system (CNS)/high grade glioma (HGG) pre-enrollment eligibility screening
-
Please note:
- This required age range applies to pre-enrollment eligibility for all HGG patients. Individual treatment protocols may have different age criteria.
- Non-DIPG patients with tumors that do not harbor an H3K27M-mutation and are >= 18 years of age will not be eligible to enroll on ACNS1821 (Step 1).
-
-
PRE ENROLLMENT: Patient is suspected of having localized, newly diagnosed HGG, excluding metastatic disease, OR patient has an institutional diagnosis of DIPG
- Please note: there are specific radiographic criteria for DIPG patient enrollment on ACNS1821 (Step 1)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
-
PRE ENROLLMENT:
- For patients with non-pontine tumors: Patients and/or their parents or legal guardians must have signed informed consent for eligibility screening on APEC14B1 Part A.
- For patients with DIPG: Patients and/or their parents or legal guardians must have signed informed consent for ACNS1821.
- Note: As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
-
PRE ENROLLMENT:
- For patients with non-pontine tumors only, the specimens obtained at the time of diagnostic biopsy or surgery must be submitted through APEC14B1 ASAP, preferably within 5 calendar days of definitive surgery
-
STEP 1: Patients must be >= 12 months and =< 21 years of age at the time of enrollment
-
STEP 1: Patients must have newly-diagnosed DIPG or HGG (including DMG).
-
STEP 1: Stratum DIPG (Closed with Amendment #4)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
- Patients with newly-diagnosed typical DIPG, defined as tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons on at least 1 axial T2 weighted image, are eligible. No histologic confirmation is required.
- Patients with pontine tumors that do not meet radiographic criteria for typical DIPG (e.g., focal tumors or those involving less than 2/3 of the pontine cross-sectional area with or without extrapontine extension) are eligible if the tumors are biopsied and proven to be high-grade gliomas (such as anaplastic astrocytoma, glioblastoma, high-grade glioma not otherwise specified [NOS], and/or H3 K27M-mutant) by institutional diagnosis.
-
STEP 1: Stratum DMG (with H3 K27M mutation) (Closed with Amendment #4)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
- Patients must have newly-diagnosed non-pontine H3 K27M-mutant HGG without BRAF V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
- Note: Patients need not have either measurable or evaluable disease, i.e., DMG patients may have complete resection of their tumor prior to enrollment. Primary spinal tumors are eligible for enrollment. For rare H3 K27M-mutant HGG in non-midline structures (e.g., cerebral hemispheres), these patients will be considered part of Stratum DMG.
-
STEP 1: Stratum HGG (without H3 K27M mutation)
-
Patients must have newly-diagnosed non-pontine H3 K27M-wild type HGG without BRAF V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
-
Please note:
- Patients who fall in this category and who are >= 18 years of age are not eligible due to another standard-of-care regimen (radiation/temozolomide) that is available
- Patients need not have either measurable or evaluable disease, i.e., HGG patients may have complete resection of their tumor prior to enrollment. Primary spinal tumors are eligible for enrollment
-
-
STEP 1: Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =<16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
-
STEP 1: Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to step 1 enrollment)
-
STEP 1: Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to step 1 enrollment)
-
STEP 1: Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days prior to step 1 enrollment)
-
STEP 1: Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 (within 7 days prior to step 1 enrollment) or
A serum creatinine based on age/sex as follows (within 7 days prior to step 1 enrollment):
-
Age / Maximum Serum Creatinine (mg/dL)
-
1 to < 2 years / male: 0.6; female: 0.6
-
2 to < 6 years / male: 0.8; female: 0.8
-
6 to < 10 years / male: 1; female: 1
-
10 to < 13 years / male: 1.2; female: 1.2
-
13 to < 16 years / male: 1.5; female: 1.4
-
>= 16 years / male: 1.7; female: 1.4
- STEP 1: Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
- STEP 1: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L.
- STEP 1: Serum amylase =< 1.5 x ULN
- STEP 1: Serum lipase =< 1.5 x ULN
- STEP 1: No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination.
- STEP 1: Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.
- STEP 1: Patients must be enrolled and protocol therapy must begin no later than 31 days after the date of radiographic diagnosis (in the case of non-biopsied DIPG patients only) or definitive surgery, whichever is the later date (Day 0).
-
For patients who have a biopsy followed by resection, the date of resection will be considered the date of definitive diagnostic surgery. If a biopsy only was performed, the biopsy date will be considered the date of definitive diagnostic surgery.
Exclusion Criteria:
-
STEP 1: Patients must not have received any prior therapy for their central nervous system (CNS) malignancy except for surgery and steroid medications.
-
STEP 1: Patients who are currently receiving another investigational drug are not eligible.
-
STEP 1: Patients who are currently receiving other anti-cancer agents are not eligible.
-
STEP 1: Patients >=18 years of age who have H3 K27M-wild type HGG.
-
STEP 1: Patients who have an uncontrolled infection.
-
STEP 1: Patients who have received a prior solid organ transplantation.
-
STEP 1: Patients with grade > 1 extrapyramidal movement disorder.
-
STEP 1: Patients with known macular degeneration, uncontrolled glaucoma, or cataracts.
-
STEP 1: Patients with metastatic disease are not eligible; MRI of spine with and without contrast must be performed if metastatic disease is suspected by the treating physician.
-
STEP 1: Patients with gliomatosis cerebri type 1 or 2 are not eligible, with the exception of H3 K27M-mutant bithalamic tumors.
-
STEP 1: Patients who are not able to receive protocol specified radiation therapy.
-
STEP 1:
- Female patients who are pregnant are ineligible since there is yet no available information regarding human fetal or teratogenic toxicities.
- Lactating females are not eligible unless they have agreed not to breastfeed their infants. It is not known whether selinexor is excreted in human milk.
- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.
- Sexually active patients of reproductive potential are not eligible unless they have agreed to use two effective methods of birth control (including a medically accepted barrier method of contraception, e.g., male or female condom) for the duration of their study participation and for 90 days after the last dose of selinexor. Abstinence is an acceptable method of birth control.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Treatment (selinexor and radiation therapy)
CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor PO on 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a MRI and may undergo a biopsy during screening. MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up. |
Undergo radiation therapy
Andre navne:
Undergo a MRI
Andre navne:
Undergo a biopsy
Andre navne:
Given orally
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum tolerated dose
Tidsramme: From day 1 of selinexor treatment until the start of maintenance therapy, assessed up to 10 weeks from treatment start date
|
Defined as the highest dose of selinexor in combination with standard of care radiation therapy that does not cause unacceptable side effects. |
From day 1 of selinexor treatment until the start of maintenance therapy, assessed up to 10 weeks from treatment start date
|
|
Event free survival (EFS)
Tidsramme: From the date of enrollment until disease progression date, secondary malignant neoplasm occurrence date, death date of any cause, or last follow-up date, assessed up to 5 years
|
Will be calculated for diffuse midline glioma/ high grade glioma patients. EFS curve will be estimated by Kaplan Meier estimates. |
From the date of enrollment until disease progression date, secondary malignant neoplasm occurrence date, death date of any cause, or last follow-up date, assessed up to 5 years
|
|
Overall Survival (OS)
Tidsramme: From the date of enrollment until death date of any cause or last follow-up date, assessed up to 5 years
|
Will be calculated for diffuse intrinsic pontine glioma patients. The OS curve will be estimated by Kaplan Meier estimates. |
From the date of enrollment until death date of any cause or last follow-up date, assessed up to 5 years
|
|
Overall response rate
Tidsramme: Up to 5 years
|
Defined as the proportion of patients whose best response is partial response or complete response. |
Up to 5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Adam L Green, Children's Oncology Group
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Neoplasmer, Neuroepithelial
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Gliom
- Undersøgelsesteknikker
- Terapeutik
- Håndtering af eksemplar
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Kirurgiske procedurer, operative
- Cytologiske teknikker
- Cytodiagnose
- Fysiske fænomener
- Diagnostiske teknikker, kirurgisk
- Kemiteknikker, analytisk
- Spektrumanalyse
- Strålebehandling
- Stråling
- Biopsi
- Magnetisk resonansspektroskopi
- Selinexor
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NCI-2021-11337
- U10CA180886 (U.S. NIH-bevilling/kontrakt)
- NCI-2021-11337 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- ACNS1821 (Anden identifikator: CTEP)
- ACNS1821 (Anden identifikator: Children's Oncology Group)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .